A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
- for people ages 18 years and up (full criteria)
- Healthy Volunteers
- healthy people welcome
- at UCLA UCSD
- study startedestimated completion
SARS-CoV-2 mRNA-1273 mRNA-1273 vaccine SARS-CoV-2 Vaccine Coronavirus Virus Diseases Messenger RNA COVID-19 COVID-19 Vaccine Moderna
- accepting new patients
- Start Date
- Completion Date
- ModernaTX, Inc.
- Click here to access the website, www.modernatx.com/cove-study, for additional information for the study, such as Study Overview, Participation, Site Locations, along with contact numbers for each location for the study.
- Phase 3
- Study Type
- Last Updated